Skip to main content
. 2016 Aug 12;4:83. doi: 10.1186/s40478-016-0348-x

Fig. 4.

Fig. 4

Deamidation of Gln147 in MBP from controls (●) and multiple sclerosis (MS) patients suffering from SPMS (○) PPMS (◊) and RRMS (▽). Deamidation of Gln147 was measured using the tryptic peptide GVDAQGTSK (i.e. GVDAQGTSK to GVDAEGTSK). Deamidation was significantly greater in the multiple sclerosis patients (p < 0.001, Mann–Whitney-U.). Deamidation increased with age in controls (R 2 = 0.571, p = 0.011)